Hookipa Pharma Inc

Hookipa Pharma — Technical Presentation (November 2020)

14 slides from Hookipa Pharma's technical presentation, Nov 30, 2020

  1. Slide 1: HB-101 CMV Vaccine Phase 2 Trial in Kidney Transplantation: Preliminary Interim Results

    HB - 101 CMV Vaccine Phase 2 Trial in Kidney Transplantation Preliminary Results of Interim Analysis November 30, 2020

  2. Slide 2: Disclaimer

    2 HOOKIPA Pharma Confidential Disclaimer This presentation and other related material may contain a number of “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 as amended, including statements regarding HOOKIPA’s expectation about any or all of t

  3. Slide 3: HB-101 Phase 2 Interim Analysis Data Overview

    3 HOOKIPA Pharma Confidential H B - 101 P h a s e 2 I n t e r i m An a l y s i s Data Overview • HB - 101 is a C ytomegalovirus (CMV) vaccine based on H O O K I P A ’s non - replicating technology • This interim analysis of the ongoing Phase 2 study of HB - 101 supports dose - finding for the 3 - do

  4. Slide 4: Cytomegalovirus (CMV) in Solid Organ Transplant Recipients

    4 HOOKIPA Pharma Confidential Cytomegalovirus (CMV) in Solid Organ Transplant Recipients Kotton CN et al. The Third International Consensus Guidelines on Management of Cytomegalovirus in Solid - organ Transplantation. T ransplantation. 2019;102:900 - 931; Ljungman P et al. Definitions of Cytomegalov

  5. Slide 5: HB-101: Arenavirus-based Prophylactic Vaccine to Prevent CMV Infections

    5 HOOKIPA Pharma Confidential • Uses our proprietary non - replicating technology, with two arenaviral vectors (LCMV) • Bi - valent vaccine incorporating 2 CMV antigens: o Glycoprotein B (“gB”) fusion protein, a B cell antigen o Phosphoprotein 65 kDa (“pp65”), a T cell antigen • Vaccine stimulates b

  6. Slide 6: Ongoing Phase 2 Clinical Trial: Prophylactic CMV Vaccine in Kidney Transplant Patients

    6 HOOKIPA Pharma Confidential Patients Eligible for a Kidney Transplant from a Live Donor Randomized to HB - 101 or Placebo Pre - transplant Stratified by Post - transplant Treatment Intent Measure decrease of post - transplant viremia in the absence and presence of antivirals Endpoints • Primary: i

  7. Slide 7: Phase 2 Interim Analysis: Safety and First Efficacy Analysis Populations

    7 HOOKIPA Pharma Confidential 57 Patients Transplanted 42 Safety Population Efficacy Population Placebo 3 pre - emptive & 11 prophylactic 14 HB - 101 8 pre - emptive & 19 prophylactic 27 HB - 101 2 Doses 19 HB - 101 3 Doses 8 Patients ≥2 Doses 41 Patients Enrolled 69 R+ Patients Pre - Transplant 12

  8. Slide 8: Phase 2 Interim Analysis Preliminary Safety

    8 HOOKIPA Pharma Confidential Safety Population : • 69 patients prior to kidney transplantation Most common mild AEs : • Influenza - like illness (N=2) • Injection site pain (N=2) Human Leukocyte Antigen (HLA) Sensitization : • HLA - sensitization is a known complication in renal dialysis patients a

  9. Slide 9: HB-101 CMV-Neutralizing Antibody Responses: 3 Doses Induce 100% Seroconversion

    9 HOOKIPA Pharma Confidential 33 R - patients measured on the day of transplant • 21 patients received vaccine • 12 patients received placebo Seroconversion Rates CMV Antibody Levels Rate s of CMV - neutralizing antibodies development: • 100% in 3 dose group (N=6) • 20% in 2 dose group (N=15) 3 dose

  10. Slide 10: Preliminary Efficacy: Reduced CMV Infection, Antiviral Use, and No CMV Disease

    10 HOOKIPA Pharma Confidential 0% 5% 10% 15% 20% 25% 30% Placebo* 3 doses HB - 101 Phase 2 Interim Analysis Preliminary Efficacy: Reduced Incidence of CMV Infection, Reduced Use of Antivirals, and No CMV Disease CMV Viremia Required Use of Antivirals CMV Disease 0% 5% 10% 15% 20% 25% 30% Placebo* 3

  11. Slide 11: HB-101 Appears Well Tolerated, Immunogenic and Efficacious (Preliminary Data)

    11 HOOKIPA Pharma Confidential Based on P h a s e 2 I n t e r i m An a l y s i s , HB - 101 Appears to be Well Tolerated, and in Patients Receiving Three Doses, Immunogenic and Efficacious (Preliminary Data) Safety: • HB - 101 appears to be well tolerated with a low incidence of adverse events (most

  12. Slide 12: Phase 2 Dataset Continues to Build and Inform Path to Registration

    12 HOOKIPA Pharma Confidential HB - 101 Phase 2 Dataset Continues to Build and Inform Path to Registration • Interim Phase 2 safety and immunogenicity data have been reviewed with investigators: o Encouraged to complete the pre - transplant three dose vaccination protocol (whenever possible in the c

  13. Slide 13: 2021 Outlook: Catalysts and Upcoming Immuno-Oncology Clinical Data

    13 HOOKIPA Pharma Confidential 2021 Outlook: Catalysts & Upcoming Immuno - Oncology Clinical Data • From non - replicating to single - vector replicating to dual vector replicating technology o HB - 101 is an immunogenic, single - vector non - replicating technology o HB - 201 is expected to be more

  14. Slide 14: HOOKIPA Pharma

    PHARMA

HOOKIPA Pharma — Technical Presentation (November 2020) on 6ix